Notícias e Atividades da Acepodia
Executivos
Veja o organograma con seus 6 executivos principais
Biografias mais buscadas da Acepodia
- Sonny Hsiao, Co-Founder, President and Chief Executive Officer
- Samuel Chen, Director
- Michael Kurman, Head, Clinical Development
Criar um alerta
para seguir os movimentos de executivos da Acepodia.
Biotecnologia
Acepodia possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).
Popular M&A news in Biotecnologia
- IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
- NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (publicado em 1 de junho de 2026)..
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Acepodia
- Acepodia Announces 2025 Clinical Development Milestones and Comprehensive Growth Strategies-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER
- Acepodia Announced CEO Dr. Sonny Hsiao’s Appointment as Chairman and Extraordinary Shareholders’ Meeting Agenda-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER
- Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease
- Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases
- Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkin's Lymphoma
- Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
- Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor
- Acepodia Announces Emerging Stock Listing on The Taipei Exchange-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER
- Acepodia Secures $100 Million Series D Financing to Advance First-in-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform
- Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non-Hodgkin's Lymphoma
- View more press releases Close
Redes sociais sobre Acepodia
- Acepodia na Wikipedia, Google News e Yahoo Finance
- Acepodia na LinkedIn, X (Twitter) e YouTube
